Company / R&D per Share
Neogen R&D per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.10
FY2024
5-year range
$0.10 / $0.24
FY2020-FY2024
Trend
-53.2%
vs FY2023
Sector context
#102 of 103
Health Care
What the data says
Among 103 Health Care companies, Neogen is in the bottom 1% for r&d per share. R&D per Share has fluctuated over the past 9 years, ranging from $0.10 in FY2024 to $0.31 in FY2020.
Based on SEC 10-K filings.
0.10 in FY2024 with a 5-year CAGR of -19.3%.
Declined from $0.24 to $0.10 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -15.4%
- 5-Year CAGR
- -19.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 103This company $0.10 Sector average $2.13
▼
-95.4% below sector average
Key checks
Key Insights
- In FY2024, r&d per share decreased 53.2% year-over-year.
- Ranks #102 out of 103 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.59 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $0.10 | -53.2% |
| FY2023 | $0.21 | -13.9% |
| FY2022 | $0.24 | +50.5% |
| FY2021 | $0.16 | -48.3% |
| FY2020 | $0.31 | +9.1% |
| FY2019 | $0.29 | +13.4% |
| FY2018 | $0.25 | -13.0% |
| FY2017 | $0.29 | +3.3% |
| FY2016 | $0.28 | +3.9% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026